Textbook of Personalized Medicine - Second Edition [2015]

723

in genetic disorders
advantages of , 530
CGH , 532
cytogenetics , 530–531
FISH with probes , 531
limitations of , 530
multiplex PCR, genomic
rearrangements , 533
mutation detection technologies ,
533–534
ROMA , 532–533
scFISH probes , 531–532
GWAS , 72–73
molecular imaging , 37, 81–82
nanobiotechnology in
cantilevers , 186
therapeutics design and monitoring ,
186–187
non-PCR methods , 36
APEX , 39
EMD , 39–40
PCR-based methods , 36
DHPLC , 38
DirectLinear™ analysis , 37
MASDA , 38
real-time PCR reaction, CNVs , 39
RFLM , 38–39
ROMA , 38
pharmacogenetics , 100–101
POC diagnosis ( see Point-of-care (POC)
diagnosis)
proteomics, application of
2DGE , 74
2D PAGE and mass spectrometry , 75
vs. genomic approaches , 75–76
mass spectrometry (MS) , 74–75
messenger RNA (mRNA) level , 73
SNP genotyping ( see Single nucleotide
polymorphisms (SNP))
Molecular imaging
cancer therapy
advantages of , 217
FDG-PET/CT role , 215–216
gallium corrole , 216
IGDD , 216
MRI functional diffusion , 214–215
CNS drug development , 601–602
commercial development of , 602–603
monitoring in vivo gene expression , 81
oncology, drug development in , 599–601
and personalized medicine , 81–82
PET , 598–599
Molecular imaging and diagnostics (MID) , 602
Molecular inversion probe (MIP) , 67

Monoclonal antibodies (MAbs) , 190,

234–235, 418

Mount Sinai Medical Center , 621

MS. See Multiple sclerosis (MS)

Mucopolysaccharidoses (MPS) , 537–538

Multi-biomarker disease activity (MBDA) , 556

Multidrug resistance (MDR) , 272–273

Multiple myeloma (MM) , 56, 332–333

Multiple sclerosis (MS) , 601

bone marrow stem cell therapy , 443

fusokine method , 444

genetic factors , 440

genome-wide association studies , 441

IFN-β therapy , 444–446

immunopathological patterns,

demyelination , 442

in vitro and ex vivo RNA expression

profi les , 440

mitoxantrone therapy , 442–443

MRI , 441

neuroprotection , 441

pharmacogenetic approach , 441–442

T cells receptors , 440

Tcelna ® , 445

Multiplex allele-specifi c diagnostic assay

(MASDA) , 38, 534

MultiPlex Initiative , 631, 687

Multiplex ligation dependent probe

amplifi cation (MLPA) assay , 289

Multiplex microarray-enhanced PCR

(MME-PCR) , 48

Multivariate index assays (MIAs) , 319,

672–674

MutSig tool , 205

Myelodysplastic syndromes (MDS) , 232, 334

Myocardial infarction (MI) , 480, 489, 500

My Prognostic Risk Signature™

(MyPRS™) , 333

MyVax ® , 242–243, 252

N

NADH dehydrogenase Fe-S protein 1

(NDUFS1) , 69

Nanobiotechnology

cancer management , 256–257

cardiovascular diseases , 505–506

in molecular diagnostics

cantilevers , 186

therapeutics design and monitoring ,

186–187

NanoChip ® Electronic Microarray , 64

NanoFlares , 212

National Biobanking Initiative , 603

Index